Phase 2 trial of ROCK inhibitor Bravyl now fully enrolled
A Phase 2a clinical trial testing Rho kinase (ROCK) inhibitor Bravyl (oral fasudil) in people with amyotrophic lateral sclerosis…
Articles by Lindsey Shapiro, PhD
Biopharmaceutical launches with goal to develop treatment for ALS
A new biopharmaceutical company has launched in the U.S. with more than $100 million in financing and a goal to…
Altered activity of ancient viral DNA in human genome tied to ALS
Alterations in the activity of ancient viral DNA that have been incorporated into the human genome may contribute to the…
Scientists validate blood test that may speed up diagnosis of ALS
Blood levels of eight small molecules called microRNAs can accurately distinguish people with amyotrophic lateral sclerosis (ALS) from healthy…
Man controls Alexa with thoughts via brain-computer interface
A man with amyotrophic lateral sclerosis (ALS) recently became the first person to control an Amazon Alexa device with…
Home care model could offer more comfort for ALS patients: Pilot study
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated…
Stabilizing cell connections eases motor dysfunction in mouse model
A gene therapy aimed at stabilizing connections between motor nerve cells and interneurons — a type of cell that regulates…
Selenium levels found elevated in ALS patients treated with Qalsody
Both beneficial and neurotoxic forms of the mineral selenium were increased in people with SOD1-associated amyotrophic lateral sclerosis (ALS)…
Discontinued therapy BIIB078 not effective in ALS, trial data show
The investigational therapy BIIB078 was generally well tolerated in a Phase 1 clinical trial, but did not show evidence of…
Clene to submit new CNM-Au8 data to FDA ahead of meeting
Clene said it planned to give the U.S. Food and Drug Administration (FDA) new data on CNM-Au8 for…